Skip to main content

Change in Orion Group Executive Management Board as of 1 June 2020: Professor Outi Vaarala appointed as Senior Vice President for Research and Development

Written by Customer Service on . Posted in Public Companies.

ORION CORPORATION      STOCK EXCHANGE RELEASE   25 MAY 2020 AT  4.20 p.m. EEST              Change in Orion Group Executive Management Board as of 1 June 2020: Professor Outi Vaarala appointed as Senior Vice President for Research and DevelopmentProfessor Outi Vaarala, M.D., Ph.D. has been appointed Senior Vice President for Research and Development and member of the Executive Management Board of the Orion Group, as of 1 June 2020. Vaarala has held the position of Vice President, Oncology Research in Orion’s Research and Development as of 10 June 2019. Prior to Orion, Vaarala led drug discovery and development from target identification to clinical Phase 2 studies in Respiratory Inflammation and Autoimmunity therapy area, first at AstraZeneca, Sweden, and later at Medimmune/AstraZeneca, USA.Outi Vaarala is a medical doctor (University of Helsinki) and has a PhD in immunology. Outi Vaarala was appointed as a Professor of Pediatric Immunology, Linkoping University, Sweden, in 2000, and as a Professor of Autoimmune Diseases, Lund University, Sweden, in 2015.Timo Lappalainen, President and CEO, says:”Orion’s Research and Development is in an interesting phase. Our operations have been developed into a recognized world-class organization that has also achieved remarkable results. Outi Vaarala has excellent background and experience from various leadership positions in Research and Development in the international pharmaceutical industry as well as a long experience of immunology and remarkable career in the academy. She has published more than 200 peer-reviewed scientific articles in internationally renowned scientific journals. I warmly welcome Outi as a member of Orion’s Executive Management Board.”   Outi Vaarala says:”During the past year when leading Oncology Research team at Orion, I have recognised the fabulous opportunities in Orion based on the knowledge and expertise across the organisation. This makes me excited about this new challenge ahead me. Co-operation and international networking is a key to success because nobody can develop drugs alone. Finland and Orion have a lot to offer for the proprietary drug discovery, and at the same time international networking is a crucial part of the operations of Orion’s Research and Development. In my new position, I want to emphasise this.”The CV of Outi Vaarala and a photo of her are attached.                                                                                                                                 
Orion Corporation
Timo Lappalainen                                Olli Huotari
President and CEO                              Senior Vice President, Corporate Functions
Contact person:Timo Lappalainen, President and CEO, phone +358 50 966 3692Contact person for media:
Terhi Ormio, Vice President, Communications, phone +358 50 966 4646, terhi.ormio@orion.fi
APPENDIX:The CV of Outi VaaralaOuti Vaarala Born 1962Senior Vice President for Research and Development, Orion Corporation as of 1 June 2020Career
Positions of trust
2005-2014        Permanent expert at the European Medicines Agency (EMA)             Publications
More than 200 peer-reviewed scientific articles in internationally renowned scientific journals (as in Science Translational Medicine, Cell Host Microbes, JAMA, New England Journal of Medicine, the Lancet, and Journal of Immunology).
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.AttachmentOuti Vaarala photo

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.